News

Article

Greenberger Explains Why Immunotherapy Will Be an Important Class of Therapies for Blood Cancers

Key Takeaways

  • Immunotherapy advancements in hematological cancers, especially Hodgkin lymphoma, show promising potential for treatment improvements.
  • The American Society of Hematology's annual meeting highlighted significant progress in blood cancer research.
SHOW MORE

Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.

Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies. The latest in blood cancer research, including studies involving immunotherapy for Hodgkin lymphoma, were announced at the annual meeting of the American Society of Hematology.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Image of man with text.
Image of women, with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Related Content
Kim Johnson was a caregiver for her sister while she battled stage 4 Hodgkin Lymphoma for nearly five years, from diagnosis through an autologous transplant. Catch up on all of Kim's blogs here!
July 10th 2025

Saying Goodbye to My Sister With Hodgkin Lymphoma

Kim Johnson
After nearly 11 years of living with Hodgkin lymphoma, my sister Kathleen passed away peacefully at 39, leaving me to navigate the sorrow of losing her.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice.
July 2nd 2025

Veteran Credits CAR T-Cell Therapy With Helping Him Reach Remission

Spencer Feldman
Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma: © stock.adobe.com.
June 18th 2025

FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

Spencer Feldman
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
Karen Cohn is a retired middle school special education teacher who was diagnosed with follicular lymphoma in July 2020. Catch up on all of Karen's blogs here!
June 17th 2025

When Cancer and COVID Collide: The Diagnosis That Changed It All

Karen Cohn
I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a statistic.